Rocket Pharmaceuticals, Inc. (RCKT) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.47
↓-50% vs avg
5yr avg: 2.97
30Y Low1.4·High6.0
ROE
↓
-60.3%
↑-22% vs avg
5yr avg: -49.3%
30Y Low-237%·High-33%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RCKT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rocket Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $398M | $390M | $1.2B | $2.5B | $1.3B | $1.4B | $3.0B | $1.1B | $584M | $71M | $163M |
| Enterprise Value | $345M | $337M | $1.1B | $2.5B | $1.2B | $1.2B | $2.8B | $978M | $514M | $41M | $182M |
| P/E Ratio → | -1.83 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.47 | 1.41 | 2.57 | 5.11 | 2.72 | 3.04 | 6.03 | 3.63 | 3.01 | 1.48 | 2.23 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RCKT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
RCKT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -60.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.3% | -60.3% | -54.1% | -50.0% | -47.0% | -35.3% | -36.2% | -33.2% | -61.6% | -48.8% | -47.1% |
| ROA | -52.0% | -52.0% | -47.3% | -43.9% | -42.3% | -31.1% | -30.5% | -26.7% | -42.2% | -25.5% | -35.3% |
| ROIC | -63.2% | -63.2% | -52.1% | -46.7% | -54.6% | -48.9% | -46.6% | -38.9% | -74.8% | -36.2% | -51.9% |
| ROCE | -58.9% | -58.9% | -54.4% | -50.4% | -45.4% | -32.4% | -29.8% | -25.8% | -42.7% | -24.3% | -36.2% |
RCKT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $78M exceeds total debt of $25M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.06 | 0.05 | 0.05 | 0.05 | 0.12 | 0.15 | 0.21 | 1.04 | 0.67 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.19 | -0.30 | -0.06 | -0.24 | -0.46 | -0.47 | -0.45 | -0.36 | -0.61 | 0.26 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -144.86 | -138.48 | -117.52 | -28.40 | -18.02 | -15.92 | -13.58 | -7.47 | -29.53 |
Net cash position: cash ($78M) exceeds total debt ($25M)
RCKT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Rocket Pharmaceuticals, Inc.'s current ratio of 6.38x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.80x to 6.38x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.38 | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 | 14.94 | 16.81 | 13.60 | 24.83 | 17.80 |
| Quick Ratio | 6.38 | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 | 14.94 | 16.81 | 13.60 | 24.83 | 17.80 |
| Cash Ratio | 2.57 | 2.57 | 9.15 | 7.69 | 9.10 | 17.54 | 14.80 | 16.61 | 13.38 | 24.57 | 17.54 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
RCKT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rocket Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $111M | $95M | $84M | $68M | $63M | $55M | $49M | $39M | $7M | $7M |
Peer Comparison
Compare RCKT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RCKTYou | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See RCKT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCKT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RCKT vs CRSP
Side-by-side business, growth, and profitability comparison vs CRISPR Therapeutics AG.
Start ComparisonRCKT — Frequently Asked Questions
Quick answers to the most common questions about buying RCKT stock.
What is Rocket Pharmaceuticals, Inc.'s P/E ratio?
Rocket Pharmaceuticals, Inc.'s current P/E ratio is -1.8x. This places it at the 50th percentile of its historical range.
What is Rocket Pharmaceuticals, Inc.'s ROE?
Rocket Pharmaceuticals, Inc.'s return on equity (ROE) is -60.3%. The historical average is -64.6%.
Is RCKT stock overvalued?
Based on historical data, Rocket Pharmaceuticals, Inc. is trading at a P/E of -1.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.